LB-100 is an inhibitor of protein phosphatase 2A (PP2A) that exhibits pro-angiogenic and anticancer activities. LB-100 increases expression of VEGF and HIF-1α. This compound also decreases growth of pancreatic cancer cells and enhances the activity of other co-administered chemotherapeutics in various cancer models.
| Cas No. | 1026680-07-8 |
|---|---|
| Purity | ≥98% |
| Formula | C13H20N2O4 |
| Formula Wt. | 268.31 |
| IUPAC Name | 3-[(4-Methyl-1-piperazinyl)carbonyl]-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid |
| Solubility | Water 53 mg/mL DMSO Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Bai X, Zhi X, Zhang Q, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett. 2014 Dec 28;355(2):281-7. PMID: 25304380.
Bai XL, Zhang Q, Ye LY, et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72. PMID: 24867249.
